false
0001477845
0001477845
2025-06-17
2025-06-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 17, 2025
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware |
001-39202 |
26-2540421 |
|
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification No.) |
101
Lindenwood Drive, Suite 225
Malvern, PA
19355
(Address of Principal Executive Offices, and
Zip Code)
(484) 875-3192
Registrant’s Telephone Number, Including
Area Code
Not
Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading Symbol(s) |
Name
of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
ANVS |
New York Stock Exchange |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| |
¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communication pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 17, 2025, Annovis Bio, Inc.
(the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) virtually. At the Annual Meeting,
two proposals were submitted to the Company’s stockholders and all matters voted upon were approved with the required votes. The
proposals are outlined below and further described in the Company’s definitive proxy statement filed with the U.S. Securities and
Exchange Commission.
At the Annual Meeting, a total of 11,588,981 shares of the Company’s
common stock, or 59.47% of the common stock outstanding as of April 28, 2025, the record date for the Annual Meeting, were represented
virtually or by proxy.
The following is a brief description of the final
voting results for each of the two proposals submitted at the Annual Meeting on June 17, 2025:
1. Election of Directors
All of the following five nominees were elected
to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until
the next Annual Meeting and until their successors have been duly elected and have qualified.
| Nominee | |
For | |
Withheld | |
Broker Non-Vote |
| Maria Maccecchini | |
4,216,112 | |
173,438 | |
7,199,431 |
| Michael Hoffman | |
4,182,806 | |
206,744 | |
7,199,431 |
| Claudine Bruck | |
4,041,007 | |
348,543 | |
7,199,431 |
| Reid McCarthy | |
4,202,391 | |
187,159 | |
7,199,431 |
| Mark White | |
3,780,238 | |
609,312 | |
7,199,431 |
2. Ratification of the Company’s Independent Auditors
The ratification of the appointment of Ernst & Young LLP was
approved by stockholders by the following vote:
| For | |
Against | |
Abstain |
| 11,382,542 | |
187,959 | |
18,480 |
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit Number |
Description |
| |
|
| 104 |
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ANNOVIS BIO, INC. |
| |
|
|
| Date: June 23, 2025 |
By: |
/s/ Maria Maccecchini |
| |
|
Name: Maria Maccecchini |
| |
|
Title: President and Chief Executive Officer |
